Carol Aghajanian
Gynecologic Medical Oncology Service
Memorial Sloan-Kettering Cancer Center
300 East 66th St
New York
Name/email consistency: high
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Aghajanian, C., Blank, S.V., Goff, B.A., Judson, P.L., Teneriello, M.G., Husain, A., Sovak, M.A., Yi, J., Nycum, L.R. J. Clin. Oncol. (2012)
- Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study. Aghajanian, C., Sill, M.W., Darcy, K.M., Greer, B., McMeekin, D.S., Rose, P.G., Rotmensch, J., Barnes, M.N., Hanjani, P., Leslie, K.K. J. Clin. Oncol. (2011)
- A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Aghajanian, C., Blessing, J.A., Darcy, K.M., Reid, G., DeGeest, K., Rubin, S.C., Mannel, R.S., Rotmensch, J., Schilder, R.J., Riordan, W. Gynecol. Oncol. (2009)
- Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. Aghajanian, C., Burris, H.A., Jones, S., Spriggs, D.R., Cohen, M.B., Peck, R., Sabbatini, P., Hensley, M.L., Greco, F.A., Dupont, J., O'Connor, O.A. J. Clin. Oncol. (2007)
- Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. Aghajanian, C., Dizon, D.S., Sabbatini, P., Raizer, J.J., Dupont, J., Spriggs, D.R. J. Clin. Oncol. (2005)
- A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Aghajanian, C., Soignet, S., Dizon, D.S., Pien, C.S., Adams, J., Elliott, P.J., Sabbatini, P., Miller, V., Hensley, M.L., Pezzulli, S., Canales, C., Daud, A., Spriggs, D.R. Clin. Cancer Res. (2002)
